STOCK TITAN
  1. Home
  2. SEC Filings
  3. VICR
  4. [144] VICOR CORP SEC Filing

VICR Form 144: Multiple 10b5-1 Sales Listed

VICR Form 144 lists proposed and completed sales of Common Stock by selling holders, many executed under 10b5-1 plans.

Filing Impact
(Neutral)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
144

Rhea-AI Filing Summary

VICR Form 144 lists proposed and completed sales of Common Stock by selling holders, many executed under 10b5-1 plans. The filing shows multiple transactions by Patrizio Vinciarelli on dates such as 06/03/2026 (20,000 shares) and 04/16/2026 (40,000 shares). The cover lists shares outstanding as 33,863,689 as of 06/04/2026.

The entries are primarily resale/10b5-1 plan sales executed through Morgan Stanley Smith Barney LLC as broker. Specific per-trade proceeds are shown per line; the filing provides a sequence of routine plan-based dispositions rather than an issuer offering.

Insights

Most trades are routine 10b5-1 plan dispositions by a named holder.

The record lists many dated sales by Patrizio Vinciarelli executed as 10b5-1 transactions through Morgan Stanley Smith Barney LLC. The pattern and repeated dates suggest scheduled plan activity rather than discretionary open-market timing.

Watch subsequent filings for any changes to plan status or large single-date volumes; the excerpt gives per-trade counts and proceeds but does not aggregate a program cap.

Shares outstanding 33,863,689 shares as of 06/04/2026
Example sale 20,000 shares sale by Patrizio Vinciarelli on 06/03/2026
Example sale 40,000 shares sale by Patrizio Vinciarelli on 04/16/2026
Founders Shares listed 20,000 shares Founders Shares line dated 11/10/1981
10b5-1 regulatory
"10b5-1 Sales for PATRIZIO VINCIARELLI 25 Frontage Road Andover"
A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.
Form 144 regulatory
"144: Securities Sold During The Past 3 Months"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Founders Shares market
"Common | 11/10/1981 | Founders Shares"
Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the VICR Form 144 show about recent insider sales?
The filing documents multiple proposed and completed sales of Common Stock, many executed under 10b5-1 plans by Patrizio Vinciarelli. It lists per-trade share counts and proceeds for specific dates such as 06/03/2026 (20,000 shares) and 04/16/2026 (40,000 shares).

Who is the broker handling the sales in the VICR Form 144?
Sales are shown as executed through Morgan Stanley Smith Barney LLC. The cover identifies the broker and includes per-trade execution details tied to that intermediary on the dated transaction lines in the filing.

Does the filing state how many VICR shares are outstanding?
Yes. The cover lists 33,863,689 shares outstanding as of 06/04/2026. That figure appears on the filing's header information and provides a baseline context for the per-trade sale quantities shown.

Are the sales in the VICR Form 144 part of an issuer offering?
No. The transactions shown are resale/selling-holder transactions executed under 10b5-1 plans and similar dispositions; the filing records holder-initiated sales rather than an issuer primary offering.

Does the Form 144 aggregate total proceeds or program limits for the sales?
The filing lists proceeds per individual transaction line but does not present an aggregate program cap or total proceeds. Each line shows shares sold and proceeds for specific dates and executions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Accepted by SEC EDGAR

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR

Keep reading

More on VICR

All VICR news

Trending in the feed

ALVO
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg Open the live feed